Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Total Liabilities (2021 - 2025)

Lyra Therapeutics has reported Total Liabilities over the past 5 years, most recently at $46.8 million for Q4 2025.

  • Quarterly results put Total Liabilities at $46.8 million for Q4 2025, down 14.48% from a year ago — trailing twelve months through Dec 2025 was $46.8 million (down 14.48% YoY), and the annual figure for FY2025 was $46.8 million, down 14.48%.
  • Total Liabilities for Q4 2025 was $46.8 million at Lyra Therapeutics, down from $48.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for LYRA hit a ceiling of $64.0 million in Q1 2024 and a floor of $5.4 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $32.8 million (2022), compared with a mean of $37.6 million.
  • Biggest five-year swings in Total Liabilities: soared 348.9% in 2022 and later decreased 19.89% in 2025.
  • Lyra Therapeutics' Total Liabilities stood at $20.6 million in 2021, then surged by 42.15% to $29.2 million in 2022, then skyrocketed by 82.04% to $53.2 million in 2023, then rose by 2.96% to $54.8 million in 2024, then decreased by 14.48% to $46.8 million in 2025.
  • The last three reported values for Total Liabilities were $46.8 million (Q4 2025), $48.0 million (Q3 2025), and $51.0 million (Q2 2025) per Business Quant data.